Liberty Wealth Management LLC Purchases Shares of 12,124 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Key Points

• Liberty Wealth Management LLC acquired 12,124 shares of Halozyme Therapeutics, valued at approximately $774,000, as part of their recent investment activities.
• Analysts have issued mixed ratings for Halozyme, with some downgrading it to a "sell," while others maintain a "buy" rating, resulting in an average rating of "Hold" and a consensus target price of $62.70.
• CEO Helen Torley sold 20,000 shares at an average price of $56.43, decreasing her ownership in the company to about 733,719 shares valued at approximately $41.4 million.

Liberty Wealth Management LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 12,124 shares of the biopharmaceutical company's stock, valued at approximately $774,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics in the 4th quarter valued at about $29,000. Bessemer Group Inc. raised its position in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 207 shares during the last quarter. Park Place Capital Corp lifted its holdings in shares of Halozyme Therapeutics by 20.1% during the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after purchasing an additional 182 shares during the period. UMB Bank n.a. increased its position in Halozyme Therapeutics by 267.4% during the 1st quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock valued at $84,000 after purchasing an additional 960 shares during the period. Finally, CWM LLC increased its stake in shares of Halozyme Therapeutics by 46.3% in the 1st quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company's stock valued at $88,000 after acquiring an additional 438 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded down $0.22 during trading hours on Thursday, hitting $62.10. The company had a trading volume of 2,070,496 shares, compared to its average volume of 1,953,332. The firm's fifty day moving average is $55.69 and its 200 day moving average is $57.83. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $70.50. The firm has a market capitalization of $7.65 billion, a price-to-earnings ratio of 14.21, a PEG ratio of 0.41 and a beta of 1.17. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 142.12%. Halozyme Therapeutics's revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.91 EPS. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $41,403,763.17. The trade was a 2.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders sold 60,000 shares of company stock worth $3,262,400. 2.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. HC Wainwright lifted their target price on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Wednesday. Wells Fargo & Company raised their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. The Goldman Sachs Group initiated coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price on the stock. Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Finally, JMP Securities upped their price objective on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $66.40.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.